Adjuvant therapy with hyaluronidase prior to excision of dermatofibrosarcoma protuberans.
BACKGROUND
Dermatofibrosarcoma protuberans (DFSP) are uncommon, low grade cutaneous malignancies, which rarely metastasize. Although surgery is the main therapy for these tumors, they commonly recur in spite of wide excisions. Hyaluronidase (HD) has been used both intralesionally as well as intravenously as an adjuvant in therapy of both epithelial and mesenchymal malignancies to decrease local spread, to potentiate differentiation induced apoptosis, and to potentiate the tissue penetration of chemotherapeutic agents. In addition, there is a long history of intralesional HD use without significant complications. The biologic characteristics of DFSP including the observation that hyaluronic acid is commonly present and sometimes is increased in these tumors and the known effects of HD therapy in other malignancies suggested to us that HD pretreatment may be a helpful adjuvant in the surgical management of DFSPs. Following diagnostic biopsy of a recurrent DFSP, the patient was treated for 4 weeks with intralesional HD injections.


RESULTS
Based on margins necessary for complete excision from past studies, this patient had decreased margin width and thus had a postoperative wound size less than was expected. The patient has had no evidence of recurrence at 24 months follow-up.
Menon
P
P
Department of Dermatology, Portsmouth Naval Medical Center, VA, USA.
Smith
K J
KJ
Crittenden
J
J
Skelton
H
H
D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018223:Dermatofibrosarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage*; D015552:Injections, Intralesional; D008875:Middle Aged; D015580:Mohs Surgery; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D006821:Hyaluronoglucosaminidase